REVERSE-Long COVID-19 With Baricitinib Study

ClinicalTrials.gov ID: NCT05858515

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05858515. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (With Baricitinib) for Long COVID Related Cognitive Impairment and ADRD (Alzheimer's Disease and Related Dementias)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.

Study identification

NCT ID: NCT05858515
Recruitment status: Withdrawn
Study type: Interventional
Phase: Phase 3
Lead sponsor: Vanderbilt University Medical Center; Other
Enrollment: Not listed

Conditions and interventions

Conditions

Post-Acute COVID-19 Syndrome

Interventions

Baricitinib 4 MG Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 21, 2024 (Actual)
Primary completion: Dec 31, 2027 (Estimated)
Completion: Dec 30, 2029 (Estimated)
Last update posted: Sep 9, 2026

2024 – 2029

United States locations

U.S. sites: 6
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
University of California San Francisco	San Francisco	California	30329	—
Yale University	New Haven	Connecticut	06520	—
Emory University	Atlanta	Georgia	30329	—
University of Minnesota	Minneapolis	Minnesota	55455	—
Vanderbilt University	Nashville	Tennessee	37203	—
Vanderbilt University Medical Center	Nashville	Tennessee	37232-8300	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05858515, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 9, 2026 · Synced Nov 14, 2026